Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial Meeting Abstract
| Authors: | Motzer, R. J.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Porta, C.; Suárez, C.; Barrios, C. H.; Richardet, M. E.; Gurney, H.; Kessler, E. R.; Tomita, Y.; Bedke, J.; Rangwala, F. A.; Askelson, M.; Panzica, J.; Fedorov, V.; Choueiri, T. K. |
| Abstract Title: | Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial |
| Meeting Title: | 2025 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2025 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-10 |
| Language: | English |
| ACCESSION: | WOS:001454809900050 |
| DOI: | 10.1200/JCO.2025.43.5_suppl.439 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 439 -- Source: Wos |
